<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">OJPathology</journal-id><journal-title-group><journal-title>Open Journal of Pathology</journal-title></journal-title-group><issn pub-type="epub">2164-6775</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ojpathology.2019.94009</article-id><article-id pub-id-type="publisher-id">OJPathology-95500</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Breast Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Pointe Noire (Congo Brazzaville)
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>C.</surname><given-names>F. S. Ngatali</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>A.</surname><given-names>F. Bolenga Liboko</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>E.</surname><given-names>Ndounga</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Y.</surname><given-names>Mabila</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>D.</surname><given-names>Moukassa</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>J.</surname><given-names>B. Nkoua-Mbon</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>P.</surname><given-names>E. G. Sounga Bandzouzi</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>L.</surname><given-names>M. A. Boumba</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Hospital General Edith Lucie Bongo, Oyo, Congo</addr-line></aff><aff id="aff2"><addr-line>Medical Oncology Department, CHU-Brazzaville, Brazzaville, Congo</addr-line></aff><aff id="aff5"><addr-line>Laboratoire d’Anatomie Pathologie, Loandjili General Hospital, Pointe Noire, Congo</addr-line></aff><aff id="aff4"><addr-line>Departement of Neurology, Loandjili General Hospital, Pointe Noire, Congo</addr-line></aff><aff id="aff1"><addr-line>Department of Oncology and Internal Medicine, Loandjili General Hospital, Pointe Noire, Congo</addr-line></aff><pub-date pub-type="epub"><day>20</day><month>09</month><year>2019</year></pub-date><volume>09</volume><issue>04</issue><fpage>76</fpage><lpage>85</lpage><history><date date-type="received"><day>4,</day>	<month>June</month>	<year>2019</year></date><date date-type="rev-recd"><day>27,</day>	<month>September</month>	<year>2019</year>	</date><date date-type="accepted"><day>30,</day>	<month>September</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial International License (CC BY-NC).http://creativecommons.org/licenses/by-nc/4.0/</license-p></license></permissions><abstract><p>
 
 
  Introduction: Breast cancer is the leading cancer and the leading cause of cancer death in women worldwide. The objective of our study was to describe the epidemiological, clinical and therapeutic aspects of breast cancer at the General Hospital of Loandjili in Pointe Noire. 
  Patients and Methods: This was a descriptive and cross-sectional study that took place in the Cancer Department of the General Hospital of Loandjili in Pointe Noire during the period from January 1st, 2012 to December 31st, 2016 for duration of 5 years. 54 records of patients over 18 years of age with histological evidence were collected. The variables studied were: age, level of education, time to presentation, telltale sign, stage of extension, histological type, and histological grade. Chi-square test was used to compare variables and groups. 
  Results: At the end of this study, we collected 54 files of breast cancer patients from 150 patients hospitalized in the Cancer Department. The frequency of breast cancer was 36%. The average age was 50 &#177; 13.6 years; the extremes were 27 years and 79 years. The most represented age group was from 37 to 40 years old with a percentage of 28%. The patient’s level of study was primary in the majority of cases (57%). The most represented histological type was invasive ductal carcinoma, (100%). The majority of patients arrived at advanced stages 44.4% and metastatic stages 26%. Patients were treated in most of cases by chemotherapy (82%), surgery (42%) and radiotherapy (10%). There was a correlation between time of presentation and stage of extension. 
  Conclusion: Breast cancer is the first cancer of the woman in Pointe Noire. Patients arrive at advanced stages; the most common histological type is invasive ductal carcinoma. The presentation time is correlated with the extension stage. These results suggest the establishment of a cancer control program in developing countries.
 
</p></abstract><kwd-group><kwd>Epidemiological</kwd><kwd> Clinical</kwd><kwd> Therapeutic</kwd><kwd> Breast Cancer</kwd><kwd> Pointe Noire</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Breast cancer is the leading cancer and the leading cause of cancer death in women worldwide [<xref ref-type="bibr" rid="scirp.95500-ref1">1</xref>] - [<xref ref-type="bibr" rid="scirp.95500-ref16">16</xref>] . This pathology was diagnosed in women at a frequency of 24.2% and was responsible for nearly 15% of deaths in 2018 [<xref ref-type="bibr" rid="scirp.95500-ref3">3</xref>] . In developing countries it is the first cancer diagnosed and the leading cause of cancer death in women [<xref ref-type="bibr" rid="scirp.95500-ref2">2</xref>] . In these low-income countries, breast cancer is often diagnosed at advanced stages and has a poor prognosis [<xref ref-type="bibr" rid="scirp.95500-ref6">6</xref>] . Breast cancer affects both men than women [<xref ref-type="bibr" rid="scirp.95500-ref17">17</xref>] - [<xref ref-type="bibr" rid="scirp.95500-ref21">21</xref>] . Since the publication of Moukassa et al. in 2007 that ranked breast cancer in second place of cancer in Pointe Noire in Congo, no studies have yet been performed [<xref ref-type="bibr" rid="scirp.95500-ref20">20</xref>] . Our study aimed to determine the epidemiological, clinical and therapeutic aspects of breast cancer in Pointe Noire.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>This was a cross-sectional descriptive study that took place in the oncology department of loandjili General Hospital in Pointe Noire in the period from 1st January 2012 to 31st December 2016, a period of 5 years. Were included in our study: all patients old more than 18 years, all patients having a complete file that is to say comprising a histological diagnosis and an extension assessment performed using an abdominal CT scan. Were excluded from our study all patients with no histological diagnosis. All men with breast cancer were excluded. The variables studied were:</p><p>&#183; Sociodemographic parameters: age, level of education, time of presentation;</p><p>&#183; Clinical parameters revealing sign, stage of extension;</p><p>&#183; Histological type and histological grade;</p><p>&#183; The type of treatment.</p><p>The time of presentation or delay was long when it was longer than 6 months and short when it was less than 6 months and was defined as the time elapsing between the installation of the disease or signs and the diagnosis. The stage of extension was grouped in local (stage 0 and I), locoregional or advanced (stage II and III) and metastatic for stage IV.</p><p>The collection of data was made from a previously written survey sheet, containing the different variables studied. The multivariate analysis was done between the time of presentation, the stage of extension and the age. Data entry was done using the Excel version 2007 software. Qualitative variables were represented in terms of number and percentage. Quantitative variables were represented effective and on average. The statistical analysis and the data processing were carried out by the Excel 2007 software and the graphpad prism version 5 software. The statistical test used was the chi-square test.</p></sec><sec id="s3"><title>3. Results</title><p>During this study we collected 150 women cancer patients’ records. Of the 150 files, 54 files had met the inclusion criteria of our study, so the frequency in our study of breast cancer in women was 36%. The patients were followed from the date of diagnosis to the date of study, from January 1st, 2012 to December 31st, 2016 for a period of 5 years in the oncology department.</p><p>The average age of the patients was 50.35 &#177; 13.6 years. The extremes were 27 years and 79 years old. The most represented age group was the age group from 37 to 46 years with 18 cases or 33.33% (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The most represented level study in our study was the primary level 63%, followed by secondary level 26% and the upper or superior level 11% (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>The average time to presentation at the consultation was 7.01 &#177; 1.48 months. 76% of patients had a long delay, 24% of patients had a short delay in our study (<xref ref-type="table" rid="table3">Table 3</xref>).</p><p>The most frequent telltale sign was the breast nodule in 52 cases, or 96.3% of cases. The rest of the telltale sign was represented by 1 case of wide, purulent and necrotic ulceration of the breast (<xref ref-type="fig" rid="fig1">Figure 1</xref>) and 1 case of inflammatory breast. The most common histological type represented was invasive ductal carcinoma 100%. The most represented histological grade was grade III of Scarff Bloom Richardson (59.3%), followed by grade II 22.2% and grade I in 18.5% of cases (<xref ref-type="fig" rid="fig2">Figure 2</xref>). The majority of patients presented at locoregional stage in 44.4% of cases; local stage was represented in 25.5% of cases while the metastatic stage was represented in 26% of cases (<xref ref-type="table" rid="table4">Table 4</xref>). The most represented treatment was chemotherapy (82%) followed by surgery in 48% of cases, radiotherapy 18% of cases; no patient had been treated with hormone therapy (<xref ref-type="table" rid="table5">Table 5</xref>).</p><p>Patients who had a long presentation time had a local stage in 9.76% of cases, locoregional stage in 51.22% of cases and metastatic stage in 39.02% of cases while patients who had a short time of presentation had more local stages in 77% of cases, 23% of cases of stage locoregional and 0% stage cases metastatic.</p><p>The correlation was found between the time of presentation and the stage of extension of the disease. The longer time of presentation was, the more the stage of extension was advanced or metastatic. This result was statistically significant (p &lt; 0.05) (<xref ref-type="table" rid="table6">Table 6</xref>).</p><p>Comparison of patients younger than 40 years old to patients over 40 years old has allowed to note that breast cancer incidence was highest at all stages in the women over than 40 years old. There was no correlation between age and stage of extension (p &gt; 0.05) (<xref ref-type="table" rid="table7">Table 7</xref>).</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Distribution of patients according to age group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Age group</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >27 - 36</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >11.11</td></tr><tr><td align="center" valign="middle" >37 - 46</td><td align="center" valign="middle" >18</td><td align="center" valign="middle" >33.33</td></tr><tr><td align="center" valign="middle" >47 - 56</td><td align="center" valign="middle" >12</td><td align="center" valign="middle" >22.22</td></tr><tr><td align="center" valign="middle" >57 - 66</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >18.51</td></tr><tr><td align="center" valign="middle" >67 - 76</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >13</td></tr><tr><td align="center" valign="middle" >77 - 86</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1.85</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients according to level of study</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Level of study</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Primary</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >6 3</td></tr><tr><td align="center" valign="middle" >Secondary</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >2 6</td></tr><tr><td align="center" valign="middle" >Superior</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >11</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Distribution of patients according to the consultation time</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Time of presentation</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >Percentage</th></tr></thead><tr><td align="center" valign="middle" >Short</td><td align="center" valign="middle" >13</td><td align="center" valign="middle" >24</td></tr><tr><td align="center" valign="middle" >Long</td><td align="center" valign="middle" >41</td><td align="center" valign="middle" >76</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Distribution of patients by stage of extension</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Stage of extension</th><th align="center" valign="middle" >Effective</th><th align="center" valign="middle" >percentage</th></tr></thead><tr><td align="center" valign="middle" >Local</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >25.5</td></tr><tr><td align="center" valign="middle" >Locoregional</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >44.4</td></tr><tr><td align="center" valign="middle" >Metastatic</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >26</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >54</td><td align="center" valign="middle" >100</td></tr></tbody></table></table-wrap><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Distribution of patients according to treatment</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Treatment</th><th align="center" valign="middle" >Yes</th><th align="center" valign="middle" >no</th></tr></thead><tr><td align="center" valign="middle" >Surgery</td><td align="center" valign="middle" >26 (48%)</td><td align="center" valign="middle" >28 (52%)</td></tr><tr><td align="center" valign="middle" >Chemotherapy</td><td align="center" valign="middle" >44 (82%)</td><td align="center" valign="middle" >10 (18%)</td></tr><tr><td align="center" valign="middle" >Radiotherapy</td><td align="center" valign="middle" >10 (18%)</td><td align="center" valign="middle" >44 (82%)</td></tr><tr><td align="center" valign="middle" >Hormonetherapy</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" >0 (0%)</td></tr></tbody></table></table-wrap><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Distribution of patients by consultation time and extension stage</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle"  colspan="4"  >Stage of Extension</th></tr></thead><tr><td align="center" valign="middle" >Time of presentation</td><td align="center" valign="middle" >Local</td><td align="center" valign="middle" >Locoregional</td><td align="center" valign="middle" >Metastatic</td><td align="center" valign="middle" >Total</td></tr><tr><td align="center" valign="middle" >Short</td><td align="center" valign="middle" >10 (77%)</td><td align="center" valign="middle" >3 (23%)</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" >13 (100%)</td></tr><tr><td align="center" valign="middle" >Long</td><td align="center" valign="middle" >4 (9.76%)</td><td align="center" valign="middle" >21 (51.22%)</td><td align="center" valign="middle" >16 (39.02%)</td><td align="center" valign="middle" >41 (100%)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >54</td></tr></tbody></table></table-wrap><p>P &lt; 0.05 test statistically significant.</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Distribution of patients by age and stage of extension</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="5"  >Stage of extension</th></tr></thead><tr><td align="center" valign="middle" >Age</td><td align="center" valign="middle" >Local</td><td align="center" valign="middle" >Locoregional</td><td align="center" valign="middle" >Metastatic</td><td align="center" valign="middle" >Total</td></tr><tr><td align="center" valign="middle" >Age &lt; 40</td><td align="center" valign="middle" >5 (31.25%)</td><td align="center" valign="middle" >9 (56.25%)</td><td align="center" valign="middle" >2 (12.5%)</td><td align="center" valign="middle" >16 (29.7%)</td></tr><tr><td align="center" valign="middle" >Age &gt; 40</td><td align="center" valign="middle" >9 (23.7)</td><td align="center" valign="middle" >15 (39.5%)</td><td align="center" valign="middle" >14 (36.8%)</td><td align="center" valign="middle" >38 (70.37%)</td></tr><tr><td align="center" valign="middle" >Total</td><td align="center" valign="middle" >14</td><td align="center" valign="middle" >24</td><td align="center" valign="middle" >16</td><td align="center" valign="middle" >54</td></tr></tbody></table></table-wrap><p>p &gt; 0.05 statistically insignificant result.</p></sec><sec id="s4"><title>4. Discussion</title><p>Our study presented some limitations. Indeed, the sample size of our hospital study was small. The lack of immunohistochemistry has failed to achieve the molecular classification that should determine the prognostic and predictive factors of breast cancer. Despite of this small sample, this study has described some epidemiological, clinical and therapeutic aspects of breast cancer in Pointe Noire which is a city of about one million inhabitants.</p><p>During our study, which took place at the General Hospital of Loandjili in the Cancer Department, we received a total of 150 women cancer patients.</p><p>Of the 150 patients, 54 had breast cancer and met all the inclusion criteria of our study. Thus, the incidence of breast cancer in women during our study was 36%.</p><p>Breast cancer was the first cancer of women in our study as in many studies [<xref ref-type="bibr" rid="scirp.95500-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.95500-ref3">3</xref>] .</p><p>The average age of the patients in our study was 50.35 &#177; 13.6 years; the extremes were 27 years and 79 years. Women were affected at a relatively young age, this was also found by most authors in developing countries (Africa) with the averages age of 47.5 &#177; 12.36 and 47.97 described respectively by Ngowa J. et al. [<xref ref-type="bibr" rid="scirp.95500-ref22">22</xref>] and Cameroon and Mensah et al. in Ghana [<xref ref-type="bibr" rid="scirp.95500-ref23">23</xref>] . In developed countries in the US for example, the average age was 61 years old with the extremes of 55 years and 64 years [<xref ref-type="bibr" rid="scirp.95500-ref24">24</xref>] . In Saudi Arabia the average age found was also relatively young 47.16 &#177; 12.15 [<xref ref-type="bibr" rid="scirp.95500-ref25">25</xref>] . The age group most represented in our study was 37 to 46 years of age, followed by the age group 47 to 56, these age groups were also young.</p><p>These age groups were close to the age groups of the majority of African countries [<xref ref-type="bibr" rid="scirp.95500-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.95500-ref23">23</xref>] . In the USA, the most affected age group was 54 to 65 [<xref ref-type="bibr" rid="scirp.95500-ref24">24</xref>] . Age groups in both developed countries are quite high age groups, unlike age groups in African countries. This could be explained on the one hand by the composition of the African population which is a young population and on the other hand by the probable increase in the incidence of breast cancer in this age group, but also by the development of diagnostic and therapeutic techniques. Indeed, the population of developed countries is aging and age is a risk factor for breast cancer.</p><p>The most represented level of education in our study was the primary level in 63% of cases, followed by the secondary level. In developing countries, patients had a primary level of education or were illiterate [<xref ref-type="bibr" rid="scirp.95500-ref26">26</xref>] , whereas in developed countries, particularly in the US, the highest level of education is the highest level [<xref ref-type="bibr" rid="scirp.95500-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.95500-ref28">28</xref>] .</p><p>The presentation time in our study was long in the majority of cases 76%, with an average of 7.01 &#177; 1.048 months. Other studies also found a long delay with an average delay of 13 &#177; 8 months [<xref ref-type="bibr" rid="scirp.95500-ref29">29</xref>] .</p><p>This could be explained on the one hand by a primary level of study in our study thus generating a low knowledge of cancer pathology and early clinical signs; on the other hand the low socio-economic level may be considered as a barrier to consultation since access to a health center and cancer care remains very expensive [<xref ref-type="bibr" rid="scirp.95500-ref30">30</xref>] [<xref ref-type="bibr" rid="scirp.95500-ref31">31</xref>] .</p><p>The most prominent revealing sign was a breast nodule in the majority of cases (98% of cases); the rest was represented by a large and purulent ulceration of breast aspect (1%) and an inflammatory breast aspect (1%).</p><p>The predominance of breast mass or breast nodule has been found in the literature [<xref ref-type="bibr" rid="scirp.95500-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.95500-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.95500-ref32">32</xref>] .</p><p>The histological type most represented in our study was 100% invasive ductal carcinoma. These results are identical to those of the literature [<xref ref-type="bibr" rid="scirp.95500-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.95500-ref32">32</xref>] .</p><p>The histological grade III according to Bloom Richardson’s scarff grading was the most represented in our study with 59.22% of cases. The literature has also found a predominance of grade III [<xref ref-type="bibr" rid="scirp.95500-ref25">25</xref>] [<xref ref-type="bibr" rid="scirp.95500-ref32">32</xref>] . The breast cancer seen in our study appeared to be aggressive and therefore poor prognosis.</p><p>The majority patients were seen in advanced stages II and III (locoregional) with a percentage of 44.4% and metastatic 26% of cases, the local stages accounted for 14% of cases in our study. Several studies in developing countries have similar results to those of our study [<xref ref-type="bibr" rid="scirp.95500-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.95500-ref26">26</xref>] . The work of Al. Isawi et al. in Saudi Arabia, found a predominance of advanced stages [<xref ref-type="bibr" rid="scirp.95500-ref25">25</xref>] . Percentages ranging from 31% to 75% have been found in Nigeria, Peru, Libya and Brazil [<xref ref-type="bibr" rid="scirp.95500-ref33">33</xref>] . In our study and in most developing countries, patients present with advanced and metastatic whereas in developed or industrialized countries such as Canada, Norway, Great Britain and Sweden, patients present themselves at local stage. Only 8% to 22% of patients are diagnosed at advanced stages in these developed countries [<xref ref-type="bibr" rid="scirp.95500-ref34">34</xref>] .</p><p>The most common treatment used in our study was chemotherapy in 52% of cases, followed by surgery in 48% of cases and a radical mastectomy in 100% of cases.</p><p>The presentation at the advanced or metastatic stages of the disease would be a factor favoring the use of chemotherapy in neo-adjuvant situation when the tumor was not operable immediately or in an adjuvant situation when the tumor had pejorative prognostic factors, is it the cases of the histological grade in our study which was the grade III and the stage of extension. According to the work of Ngowa et al. in Cameroon, surgery was used in (64.70%) cases; the chemotherapy was used in neo-adjuvant (53.39%) or adjuvant (35.74%) [<xref ref-type="bibr" rid="scirp.95500-ref22">22</xref>] . As radiotherapy was not available in the Congo, only 10% of patients were able to benefit abroad in our study.</p><p>No patient had been able to receive hormone therapy since none had been able to benefit from immunohistochemistry for the search for hormonal receptors because the technique was not available at that time in Congo.</p><p>Multivariate analysis between the presentation time and the extension stage in our study found that the longer the delay, the more advanced the stage. There was a correlation between the two variables (the delay and the extension stage).</p><p>These results were statistically significant.</p><p>Long presentation times are associated with poor prognosis [<xref ref-type="bibr" rid="scirp.95500-ref34">34</xref>] .</p><p>Breast cancer affects young women as well as older women. Age is a risk factor. As you get older, the risk of developing breast cancer increases [<xref ref-type="bibr" rid="scirp.95500-ref35">35</xref>] . In our study we found 16 cases of breast cancer in patients under 40 years of age and 38 cases of breast cancer in patients over 40 years of age. As age increases, cancer risk increases.</p><p>In our study, women over the age of 40 tended to present themselves at advanced stages.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Breast cancer is the first cancer of the women in Pointe Noire; it affects both young women and older women. The most frequent histological type is invasive ductal carcinoma; patients often consult at advanced stages. The presentation at the advanced stages should lead to the establishment of prevention programs for the fight against cancer in the majority of developing countries.</p></sec><sec id="s6"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s7"><title>Cite this paper</title><p>Ngatali, C.F.S., Liboko, A.F.B., Ndounga, E., Mabila, Y., Moukassa, D., Nkoua-Mbon, J.B., Bandzouzi, P.E.G.S. and Boumba, L.M.A. (2019) Breast Cancer: Epidemiological, Clinical, and Therapeutic Aspects in Pointe Noire (Congo Brazzaville). Open Journal of Pathology, 9, 76-85. https://doi.org/10.4236/ojpathology.2019.94009</p></sec></body><back><ref-list><title>References</title><ref id="scirp.95500-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ministry of Health (2010) Beat Breast Cancer. United Arab Emirates.</mixed-citation></ref><ref id="scirp.95500-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Jemal, A., Bray, F., Center, M.M., et al. (2011) Global Cancer Statistics. CA: A Cancer Journal for Clinicians, 61, 69-90. https://doi.org/10.3322/caac.20107</mixed-citation></ref><ref id="scirp.95500-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.  
https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="scirp.95500-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Gullatte, M., Phillips, J. and Gibson, L. (2006) Factors Associated with Delays in Screening of Self-Detected Breast Changes in African-American Women. Journal of National Black Nurses’ Association, 17, 45-50.</mixed-citation></ref><ref id="scirp.95500-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Brahim, N.A. and Odusanya, O.O. (2009) Knowledge of Risk Factors, Beliefs and Practices of Female Healthcare Professionals towards Breast Cancer in a Tertiary Institution in Lagos, Nigeria. BMC Cancer, 9, 76.  
https://doi.org/10.1186/1471-2407-9-76</mixed-citation></ref><ref id="scirp.95500-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Lauby-Secretan, B., Scoccianti, C., Loomis, D., Benbrahim-Tallaa, L., Bouvard, V., Bianchini, F., Straif, K. and International Agency for Research on Cancer Handbook Working Group (2015) Breast-Cancer Screening—Viewpoint of the IARC Working Group. The New England Journal of Medicine, 372, 2353-2358.  
https://doi.org/10.1056/NEJMsr1504363</mixed-citation></ref><ref id="scirp.95500-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Assi, H.A., Khoury, K.E., Dbouk, H., Khalil, L.E., Mouhieddine, T.H. and El Saghir, N.S. (2013) Epidemiology and Prognosis of Breast Cancer in Young Women. Journal of Thoracic Disease, 5, S2-S8.</mixed-citation></ref><ref id="scirp.95500-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">American Cancer Society (2008) Cancer Facts and Figures.</mixed-citation></ref><ref id="scirp.95500-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">American Cancer Society (2014) Cancer Facts and Figures 2014. American Cancer Society, Atlanta, GA.</mixed-citation></ref><ref id="scirp.95500-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ferlay, J., Shin, H.R., Bray, F., Forman, D., Mathers, C. and Parkin, D.M. (2010) Women and Cancer: Screening and Treatment Save Lives Estimates of Worldwide Burden of Cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127, 2893-2917. https://doi.org/10.1002/ijc.25516</mixed-citation></ref><ref id="scirp.95500-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R.L., Miller, K.D. and Jemal, A. (2015) Cancer Statistics. CA: A Cancer Journal for Clinicians, 65, 5-29. https://doi.org/10.3322/caac.21254</mixed-citation></ref><ref id="scirp.95500-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Ly, D., Forman, D., Ferlay, J., Brinton, L.A. and Cook, M.B. (2013) An International Comparison of Male and Female Breast Cancer Incidence Rates. International Journal of Cancer, 132, 1918-1926. https://doi.org/10.1002/ijc.27841</mixed-citation></ref><ref id="scirp.95500-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bewtra, C. (2010) Clinicopathologic Features of Female Breast Cancer in Kumasi, Ghana. International Journal of Cancer Research, 6, 154-160. 
https://doi.org/10.3923/ijcr.2010.154.160</mixed-citation></ref><ref id="scirp.95500-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">International Agency for Research on Cancer (2010) GLOBOCAN Cameroon Fact Sheets: Breast Cancer. Lyon, France. http://globocan.iarc.fr/</mixed-citation></ref><ref id="scirp.95500-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Parkin, D.M., Bray, F., Ferlay, J. and Pisani, P. (2005) Global Cancer Statistics, 2002. CA: A Cancer Journal for Clinicians, 55, 74-108.  
https://doi.org/10.3322/canjclin.55.2.74</mixed-citation></ref><ref id="scirp.95500-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wiredu, E.K. and Armah, H.B. (2006) Cancer Mortality Patterns in Ghana: A 10-Year Review of Autopsies and Hospital Mortality. BMC Public Health, 6, 159-165.  
https://doi.org/10.1186/1471-2458-6-159</mixed-citation></ref><ref id="scirp.95500-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Moukassa, D., Ibara, J.R., Benali, A., N’koua-Mbon, J.B., Bikindou, A.S., Lingouala, L.G., Tsiba, J.R., Eouany, M.L., Diembi, S. and Dykoka-N’golo, R. (2007) Le profil épidémiologiques des cancers A-T-IL évolué en cinquante ans a Pointe Noire au Congo Brazzaville? Médecine d'Afrique Noire, 5401, 29.</mixed-citation></ref><ref id="scirp.95500-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Togo, A., Kante, L., Dembele, B.T., Traore, A., Diakite, I., Maigra, A., Diallo, A.C. and Diallo, G. (2010) Cancer du sein dans deux centre hospitaliers de Bamako. Aspects épidémiologiques et diagnostiques. Médecine d’Afrique Noire, 5705, 249-253.</mixed-citation></ref><ref id="scirp.95500-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Moukassa, D., Mvoukoulou, B., N’koua-M’bon, J.B., Ebatetou-Ataboho, E. and Koukambassana, S. (2012) Caracteristiques cyto morphologiques des nodules palpables en consultation médicale ambulatoire. Médecine d’Afrique Noire février, 5902, 59-63.</mixed-citation></ref><ref id="scirp.95500-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Siegel, R., Naishadham, D. and Jemal, A. (2012) Cancer Statistics 2012. CA: A Cancer Journal for Clinicians, 62, 283-98. https://doi.org/10.3322/caac.21153</mixed-citation></ref><ref id="scirp.95500-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Hill, T.D., Khamis, H.J., Tyczynski, J.E. and Berkel, H. (2005) Comparison of Male and Female Breast Cancer Incidence Trends, Tumor Characteristics, and Survival. Annals of Epidemiology, 15, 773-780.  
https://doi.org/10.1016/j.annepidem.2005.01.001</mixed-citation></ref><ref id="scirp.95500-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Ngowa, J., Kasia, J., Yomi, J., Nana, A., Ngassam, A., Domkam, I., Sando, Z. and Ndom, P. (2015) Breast Cancer Survival in Cameroon: Analysis of a Cohort of 404 Patients at the Yaoundé General Hospital. Advances in Breast Cancer Research, 4, 44-52. https://doi.org/10.4236/abcr.2015.42005</mixed-citation></ref><ref id="scirp.95500-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Mensah, A., Yarney, J., Nokoe, S., Opoku, S. and Clegg-Lamptey, J. (2016) Survival Outcomes of Breast Cancer in Ghana: An Analysis of Clinicopathological Features. Open Access Library Journal, 3, 1-11.</mixed-citation></ref><ref id="scirp.95500-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Rugo, H.S., Majure, M., Buxton, M. and Esserman, L. (2017) Neoplasme of Breast. Cancer Medicine, 9, 1368-1438.</mixed-citation></ref><ref id="scirp.95500-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Al-Isawi, A. (2016) Breast Cancer in Western Iraq: Clinicopathological Single Institution Study. Advances in Breast Cancer Research, 5, 83-89.  
https://doi.org/10.4236/abcr.2016.52009</mixed-citation></ref><ref id="scirp.95500-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Gueye, M., Gueye, S., Diallo, M., Thiam, O., Mbodji, A., Diouf, A., Fall, K., Toure, Y., Daff, H. and Moreau, J. (2017) Sociodemographic Factors Associated with Delays in Breast Cancer. Open Journal of Obstetrics and Gynecology, 7, 455-463.  
https://doi.org/10.4236/ojog.2017.74047</mixed-citation></ref><ref id="scirp.95500-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Dieterich, M., Stubert, J., Reimer, T., et al. (2014) Influence of Life Style Factors on Breast Cancer Risk. Breast Cancer, 9, 407-414. https://doi.org/10.1159/000369571</mixed-citation></ref><ref id="scirp.95500-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Cuzick, J. (2008) Assessing Risk for Breast Cancer. Breast Cancer Research, 10, S13. 
https://doi.org/10.1186/bcr2173</mixed-citation></ref><ref id="scirp.95500-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Mayi-Tsonga, S., Belembaogo, E., Meyé, J.-F., Ngou-Mvé-Ngou, J.-P., Nguizi-Ogoula, S. and Bisse, A. (2009) Les cancers du sein au Gabon: Aspects epidemiologiques, diagnostiques et therapeutiques. Journal africain du cancer, 1, 11-15.  
https://doi.org/10.1007/s12558-008-0003-y</mixed-citation></ref><ref id="scirp.95500-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Abulkhair, O.A., Al Tahan, F.M., Young, S.E., Musaad, S.M. and Jazieh, A.-R.M. (2010) The First National Public Breast Cancer Screening Program in Saudi Arabia. Annals of Saudi Medicine, 30, 350-357. https://doi.org/10.4103/0256-4947.67078</mixed-citation></ref><ref id="scirp.95500-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Mukem, S., Sriplung, H., McNeil, E. and Tangcharoensathien, V. (2014) Breast Cancer Screening among Women in Thailand: Analyses of Population Based Household Surveys. Journal of the Medical Association of Thailand, 97, 1106-1118.</mixed-citation></ref><ref id="scirp.95500-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Sano, D., Cisse, R., Dao, B., Lankoande, J., Traore, S.S., Soudre, R.B. and Sanou, A. (1998) Le cancer du sein problème diagnostics et thérapeutiques au CHU de Ouagadougou. Médecine d’Afrique Noire, 45, 297-301.</mixed-citation></ref><ref id="scirp.95500-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Unger-Saldana, K. (2014) Challenges to the Early Diagnosis and Treatment of Breast Cancer in Developing Countries. World Journal of Clinical Oncology, 5, 465-477.  
https://doi.org/10.5306/wjco.v5.i3.465</mixed-citation></ref><ref id="scirp.95500-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">Olivotto, I.A., Gomi, A., Bancej, C., et al. (2002) Influence of Delay to Diagnosis on Prognostic Indicators of Screen-Detected Breast Carcinoma. Cancer, 94, 2143-2150.  
https://doi.org/10.1002/cncr.10453</mixed-citation></ref><ref id="scirp.95500-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Dia, J., Toure, M., Yao, I., Bohoussou, E., Saki, C., Oyelade, M., Okon, G. and Anonga, S. (2017) Breast Cancer in Young Women under 40 Years in Sub-Saharan Africa. Journal of Cancer Therapy, 8, 714-725.</mixed-citation></ref></ref-list></back></article>